98%
921
2 minutes
20
Toll-like receptor (TLR)7 contributes to type I interferon (IFN) expression in systemic lupus erythematosus (SLE). This study investigated genetic variability of TLR7 in 319 juvenile-onset (j)SLE patients from the UK. New generation sequencing was used to associate "common" TLR7 variants with demographic and clinical features. Three jSLE-associated variants with in silico predicted impact on gene function presented minor allele frequencies ≥5 %: rs2302267/n.-20T > G (TLR7 promoter); rs179008/p.Gln11Leu (missense variant with predicted loss-of-function); and rs3853839/c.∗881C > G (TLR7 3'UTR). The risk to develop jSLE was increased in African/Caribbean girls carrying rs3853839 GC/GG (OR: 1.8; 95 %-CI: 1.2-2.9), while the risk associated with this variant was reduced in European girls (OR: 0.5; 95 %-CI: 0.4-0.7). At inclusion, rs3853839 minor G allele carrier status associated with activity in the mucocutaneous BILAG domain (p = 0.004), "older" age at diagnosis (p = 0.003, Asian), C3 consumption (p = 0.015, boys), and higher anti-dsDNA antibody levels (p = 0.015, African/Caribbean). The negative linkage disequilibrium between rs179008 (T-C/TT) and rs3853839 (CC) associated with increased global disease activity (pBILAG-2004), and activity in the constitutional and musculoskeletal pBILAG domains. Functionally, rs2302267/n.-20T > G, may protect from leukopenia through reduced TLR7 promoter activity, while rs3853839/c.∗881C > G-3'UTR increases TLR7 mRNA stability contributing to increased gene expression. In conclusion, common TLR7 variants may influence jSLE risk and organ involvement in an ancestry-specific manner. Observations argue for genetic risk stratification and future consideration of gene variants affecting TLR7 to guide personalized treatment and care strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaut.2025.103451 | DOI Listing |
Adv Mater
September 2025
State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
Delivering therapeutics across the blood-brain barrier (BBB) remains a major challenge in ischemic stroke therapy. Ischemic stroke induces upregulation of various inflammatory membrane receptors on brain endothelial cells, offering potential entry points for receptor-mediated transcytosis. This study proposes a universal targeting strategy by employing inflammatory pathway antagonists as targeting ligands, which broadens the spectrum of available ligands beyond traditional receptor-binding molecules.
View Article and Find Full Text PDFiScience
September 2025
Department of Animal Science, University of Connecticut, 1390 Storrs Road, Storrs, CT 06269-4163, USA.
Recent studies suggested that treating sperm with R848, a ligand for the X-linked Toll-like receptors 7 and 8 (TLR7/8) in mice, goats, and cattle, could selectively reduce the motility of X chromosome bearing sperm (X-sperm). This reduction enables the separation of X- and Y-sperm and thereby sex selection. However, through three species and multiple methods, our results challenged prior published data.
View Article and Find Full Text PDFCell Res
September 2025
Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
The pre-dimerization of endosome-localized RNA sensor Toll-like receptor 3 (TLR3) is required for its innate recognition, yet how TLR3 pre-dimers are formed and precisely primed for innate activation remains unclear. Here, we demonstrate that endosome-localized self RNA Rmrp directly binds to TLR3 and induces TLR3 dimerization in the early endosome but does not interact with endosome-localized TLR7, TLR8, TLR9 or cytoplasmic RNA sensor RIG-I under homeostatic conditions. Cryo-EM structure of Rmrp-TLR3 complex reveals a novel lapped conformation of TLR3 dimer engaged by Rmrp, which is distinct from the activation mechanism by dsRNA and the specific structural feature at the 3'-end of Rmrp is critical for its functional interaction with TLR3.
View Article and Find Full Text PDFCarbohydr Polym
November 2025
State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China. Electronic address:
Combining radiotherapy with immunotherapy holds promise for treating solid tumors and metastases, but challenges persist, including hypoxia-induced immunosuppression and immune-related adverse events from off-target toxicity. To address this, we engineered an in-situ formed hydrogel by crosslinking hyaluronic acid and polyvinyl alcohol with a reactive oxygen species (ROS)-responsive linker (3-aminophenylboronic acid). This hydrogel leverages radiotherapy-induced ROS within the tumor microenvironment to trigger localized release of nitric oxide (NO) and the toll-like receptor 7/8 (TLR7/8) agonist R848.
View Article and Find Full Text PDFExpert Opin Ther Pat
September 2025
Department of Chemistry and Centre of Advanced Studies, Panjab University, Chandigarh, India.
Introduction: Toll-like receptors (TLRs) play key role in cancer immunotherapy by harnessing the immune system's natural response to target and fight tumors. Among various TLRs, mainly TLR3, TLR4, TLR7, TLR8, and TLR9, have been investigated for their ability to modulate immune responses, improve tumor recognition, and enhance the efficacy of conventional treatments like chemotherapy and radiotherapy.
Areas Covered: This review provides in-depth analysis of patents filed from 2014 to 2024 that explored TLR-targeting strategies in cancer therapy.